https://www.selleckchem.com/pr....oducts/Cyclosporin-A
Low-dose, weekly cisplatin (40 mg/m ) regimens are currently utilized at Eskenazi Health in Indianapolis, Indiana for the treatment of head and neck cancer due to enhanced tolerability. This retrospective analysis analyzes the incidence, severity, and risk factors for AKI in patients who received this regimen. A retrospective chart review was conducted including patients with head and neck cancer treated with weekly, low dose cisplatin (40 mg/m ) with concurrent radiotherapy (RT). From this criteria, 22 patients we
Like
Comment
Share
